Ekso Bionics Narrows Q3 Loss, But Going Concern Doubts Persist

TL;DR

**EKSO is burning cash faster than it's growing revenue, making it a high-risk bet unless new financing materializes ASAP.**

AI Summary

Ekso Bionics Holdings, Inc. reported a net loss of $1.421 million for the three months ended September 30, 2025, an improvement from a $2.072 million net loss in the prior-year period. However, for the nine months ended September 30, 2025, the net loss widened to $7.021 million from $7.917 million in the same period of 2024. Revenue for the three months ended September 30, 2025, increased slightly to $4.227 million from $4.129 million year-over-year, but decreased significantly for the nine-month period to $9.659 million from $12.835 million. The company's cash position decreased to $2.722 million as of September 30, 2025, from $4.493 million at December 31, 2024, and it used $7.470 million in cash from operations during the nine months ended September 30, 2025. A significant strategic move was the payoff of the $2.000 million Banc of California secured term loan on September 12, 2025, using restricted cash, which eliminated associated liquidity covenants. Despite a reduction in operating expenses by $897 thousand for the three-month period, the company continues to face substantial doubt about its ability to continue as a going concern, with current cash projected to fund operations only into the first quarter of 2026.

Why It Matters

For investors, EKSO's persistent operating losses and dwindling cash reserves, with only $2.722 million on hand and a going concern warning, signal high risk. The company's ability to raise additional funding or secure strategic partnerships is critical for survival, impacting future product development and market competitiveness against larger medical device firms. Employees face uncertainty given the financial instability and potential for further cost reduction efforts. Customers relying on Ekso's exoskeleton technology could see disruptions if the company fails to secure long-term funding, affecting product availability and support. The broader market for medical exoskeletons, while growing, will watch closely to see if EKSO can navigate its financial challenges or if it becomes an acquisition target.

Risk Assessment

Risk Level: high — The company explicitly states "substantial doubt regarding our ability to continue as a going concern" and projects cash will fund operations only "into the first quarter of 2026." This is evidenced by an accumulated deficit of $257.722 million and $7.470 million in cash used in operations during the nine months ended September 30, 2025.

Analyst Insight

Investors should exercise extreme caution and consider avoiding EKSO shares due to the explicit going concern warning and limited cash runway. Those holding shares should evaluate their risk tolerance and consider divesting, as the need for immediate financing on acceptable terms is uncertain and critical for the company's survival.

Financial Highlights

debt To Equity

1.24

revenue

$9.659M

operating Margin

-91.3%

total Assets

$21.661M

total Debt

$11.982M

net Income

-$7.021M

eps

N/A

gross Margin

53.6%

cash Position

$2.722M

revenue Growth

-24.7%

Key Numbers

• $2.722M — Cash on hand (Decreased from $4.493M at Dec 31, 2024, highlighting liquidity concerns.)
• $257.722M — Accumulated Deficit (Indicates significant historical losses and ongoing financial strain.)
• $7.470M — Cash used in operating activities (For the nine months ended Sept 30, 2025, demonstrating negative operational cash flow.)
• $1.421M — Net loss (Q3 2025) (Improved from $2.072M in Q3 2024, but still a loss.)
• $7.021M — Net loss (9 months 2025) (Worsened from $7.917M in the same period of 2024, indicating increasing losses.)
• $4.227M — Revenue (Q3 2025) (Slight increase from $4.129M in Q3 2024, showing minimal growth.)
• $9.659M — Revenue (9 months 2025) (Significant decrease from $12.835M in the same period of 2024, indicating a revenue decline.)
• Q1 2026 — Cash runway estimate (Management estimates cash will fund operations only into this quarter, signaling urgent need for capital.)
• $2.000M — Banc of California loan paid off (Eliminated liquidity covenants but used restricted cash, impacting overall cash position.)
• 2,623,233 — Common shares outstanding (As of October 27, 2025, reflecting potential dilution from equity financings.)

Key Players & Entities

• Ekso Bionics Holdings, Inc. (company) — registrant of the 10-Q filing
• Banc of California (company) — lender for the secured term loan
• Nasdaq Capital Market (regulator) — exchange where EKSO is listed
• $2.722 million (dollar_amount) — cash on hand as of September 30, 2025
• $257.722 million (dollar_amount) — accumulated deficit as of September 30, 2025
• $7.470 million (dollar_amount) — cash used in operations for the nine months ended September 30, 2025
• $2.000 million (dollar_amount) — amount of secured term loan paid off on September 12, 2025
• $4.227 million (dollar_amount) — revenue for the three months ended September 30, 2025
• $9.659 million (dollar_amount) — revenue for the nine months ended September 30, 2025
• September 30, 2025 (date) — end of the reporting period

FAQ

Risk Factors

• Substantial doubt about going concern [high — financial]: The company has incurred significant net losses, with a $1.421 million loss in Q3 2025 and a $7.021 million loss for the nine months ended September 30, 2025. Cash on hand decreased to $2.722 million as of September 30, 2025, and management projects this will only fund operations into Q1 2026, indicating a high risk of insolvency without additional financing.
• Declining revenue and negative operating cash flow [high — financial]: Revenue for the nine months ended September 30, 2025, decreased significantly to $9.659 million from $12.835 million in the prior year. The company also used $7.470 million in cash from operations during the same period, highlighting a persistent inability to generate cash from its core business activities.
• Dependence on future financing [high — financial]: The company's projected cash runway into Q1 2026 suggests an immediate need for substantial capital infusion. Failure to secure adequate financing could impede its ability to continue operations, develop products, and meet its obligations.
• Inventory management and cost of revenue [medium — operational]: While revenue saw a slight increase in Q3 2025, the cost of revenue was $1.678 million, leading to a gross profit of $2.549 million. Inventories increased to $5.023 million from $4.571 million, suggesting potential challenges in inventory turnover or valuation.
• Accumulated deficit [high — financial]: The company has an accumulated deficit of $257.722 million as of September 30, 2025. This substantial historical loss indicates a long-term struggle to achieve profitability and raises concerns about the sustainability of the business model.

Industry Context

Ekso Bionics operates in the highly competitive and rapidly evolving exoskeleton and robotic rehabilitation technology market. Key trends include increasing adoption in physical therapy, neurological rehabilitation, and industrial applications. However, the industry faces challenges related to high product costs, reimbursement policies, and the need for extensive clinical validation and regulatory approvals.

Regulatory Implications

The company must navigate complex regulatory pathways for medical devices, including FDA approvals and international certifications. Compliance with evolving healthcare regulations and reimbursement policies is critical for market access and revenue generation. Any delays or failures in obtaining regulatory clearance can significantly impact product launch timelines and commercial success.

What Investors Should Do

1. Monitor upcoming financing activities closely.
2. Evaluate the sustainability of revenue growth and cost management.
3. Assess the competitive landscape and technological differentiation.
4. Review management's strategy for addressing the going concern issue.

Key Dates

• 2025-09-30: End of Q3 2025 — Reported $1.421M net loss and $4.227M revenue. Cash position stood at $2.722M.
• 2025-09-12: Payoff of Banc of California loan — Eliminated $2.000M loan and associated covenants using restricted cash, impacting liquidity.
• 2026-01-01: Projected cash runway end (Q1 2026) — Management estimates current cash will only fund operations until this period, signaling an urgent need for capital.
• 2025-12-31: End of Fiscal Year 2024 — Cash position was $4.493M, with total assets of $26.652M and total liabilities of $13.945M.

Glossary

Accumulated deficit

The total cumulative net losses of a company since its inception, minus any cumulative net profits. (Indicates Ekso Bionics has historically operated at a loss, with a significant deficit of $257.722 million as of September 30, 2025.)

Going concern

A business's ability to continue operating for the foreseeable future without the threat of liquidation. (The company faces substantial doubt about its ability to continue as a going concern due to its financial condition and projected cash runway.)

Restricted cash

Cash that a company cannot freely use because it is pledged as collateral for a loan or is otherwise designated for a specific purpose. (Ekso Bionics used its restricted cash of $2.000 million to pay off a loan, which eliminated covenants but reduced available liquid assets.)

Cash runway

The amount of time a company can continue to operate before it runs out of cash, based on its current burn rate. (Management estimates the company's cash runway extends only into Q1 2026, highlighting an immediate need for financing.)

Convertible promissory note

A debt instrument that can be converted into equity (stock) under certain conditions. (The company had a convertible promissory note of $1.937 million as of September 30, 2025, which represents potential future dilution.)

Year-Over-Year Comparison

Compared to the prior year's nine-month period, Ekso Bionics Holdings, Inc. experienced a significant revenue decline from $12.835 million to $9.659 million, a decrease of over 24%. While the net loss for the third quarter improved slightly to $1.421 million from $2.072 million, the nine-month net loss widened from $7.917 million to $7.021 million. Operating expenses were reduced, particularly in sales and marketing and R&D, but the company's cash position has fallen to $2.722 million from $4.493 million at year-end 2024, and the risk of not being a going concern has intensified.

Key Financial Figures

• $0.001 — nge on which registered Common Stock, $0.001 par value per share EKSO Nasdaq Cap
• $250 — nstitutions with each balance under the $250 Federal Deposit Insurance Corporation (
• $100 — posit insurance limits of approximately $100 at each of the Company's two foreign ba

Filing Documents

• ekso20250930_10q.htm (10-Q) — 1794KB
• ex_845053.htm (EX-31.1) — 13KB
• ex_845054.htm (EX-31.2) — 13KB
• ex_845055.htm (EX-32.1) — 6KB
• ex_845056.htm (EX-32.2) — 6KB
• 0001437749-25-031960.txt ( ) — 8694KB
• ekso-20250930.xsd (EX-101.SCH) — 71KB
• ekso-20250930_cal.xml (EX-101.CAL) — 50KB
• ekso-20250930_def.xml (EX-101.DEF) — 507KB
• ekso-20250930_lab.xml (EX-101.LAB) — 455KB
• ekso-20250930_pre.xml (EX-101.PRE) — 549KB
• ekso20250930_10q_htm.xml (XML) — 1488KB

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION Item 1.

Financial Statements

Financial Statements 4 Condensed Consolidated Balance Sheets as of September 30, 2025 (unaudited) and December 31, 2024 4 Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three and Nine Months ended September 30, 2025 and 2024 (unaudited) 5 Condensed Consolidated Statements of Stockholders' Equity for the Three and Nine Months ended September 30, 2025 and 2024 (unaudited) 6 Condensed Consolidated Statements of Cash Flows for the Nine Months ended September 30, 2025 and 2024 (unaudited) 8 Notes to Condensed Consolidated Financial Statements (unaudited) 9 Item 2. Management ' s Discussion and Analysis of Financial Condition and Results of Operations 29 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 39 Item 4.

Controls and Procedures

Controls and Procedures 39

OTHER INFORMATION

PART II. OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 40 Item 1A.

Risk Factors

Risk Factors 40 Item 5. Other Information 43 Item 6. Exhibits 44

Signatures

Signatures 45 Table of Contents

FINANCIAL INFORMATION

PART I. FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements Ekso Bionics Holdings, Inc. Condensed Consolidated Balance Sheets (In thousands, except par value) September 30, 2025 December 31, 2024 (unaudited) Assets Current assets: Cash $ 2,722 $ 4,493 Restricted cash — 2,000 Accounts receivable, net of allowances of $ 39 and $ 33 , respectively 6,048 7,238 Inventories 5,023 4,571 Prepaid expenses and other current assets 1,003 541 Total current assets 14,796 18,843 Property and equipment, net 1,237 1,577 Right-of-use assets 632 788 Intangible assets, net 4,152 4,580 Goodwill 431 431 Other assets 413 433 Total assets $ 21,661 $ 26,652 Liabilities and Stockholders' Equity Current liabilities: Accounts payable $ 1,661 $ 1,552 Accrued liabilities 1,930 2,352 Deferred revenues, current 1,700 1,956 Convertible promissory note, net 1,937 — Notes payable, current 1,250 1,250 Lease liabilities, current 461 427 Total current liabilities 8,939 7,537 Deferred revenues 1,631 1,920 Notes payable, net 1,070 3,854 Lease liabilities 237 452 Warrant liabilities — 1 Other non-current liabilities 105 181 Total liabilities 11,982 13,945 Commitments and Contingencies (Note 14) Stockholders' equity: Convertible preferred stock, $ 0.001 par value; 10,000 shares authorized; none issued and outstanding as of September 30, 2025 and December 31, 2024 — — Common stock, $ 0.001 par value; 141,429 shares authorized; 2,623 and 1,480 shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively 36 22 Additional paid-in capital 268,065 262,203 Accumulated other comprehensive (loss) income ( 700 ) 957 Accumulated deficit ( 257,722 ) ( 250,475 ) Total stockholders' equity 9,679 12,707 Total liabilities and stockholders' equity $ 21,661 $ 26,652 The accompanying notes are an integral part of these condensed consolidated financial statements. 4 Table of Contents Ekso Bionics Holdings,

View Full Filing

View this 10-Q filing on SEC EDGAR